Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CMab-43
- Development stage
- Unknown
- Lead developer
- Tohoku University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Peritoneal Injection (in Animal Studies)
01
Overview
CMab-43 is a mouse recombinant monoclonal antibody targeting **CD133** (Prominin-1), a marker for cancer stem cells. It is used primarily for research purposes, particularly in detecting CD133-expressing cells in colon cancer. CMab-43 has shown antitumor activity in mouse xenograft models of colon cancer by reducing tumor development. It is suitable for immunohistochemistry, Western blot, and flow cytometry applications.
- Other names
- Anti-CD133/PROM1 AntibodyCMab-43CMab43CMab 43
02
Targets
CD133 (CD133 antigen)
Beyond the preview
Go deeper on CMab-43.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CMab-43.